Cargando…

PD-L1 Expression and Survival among Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy()

BACKGROUND: Recent clinical trial results have suggested that programmed cell death ligand 1 (PD-L1) expression measured by immunohistochemistry may predict response to anti–programmed cell death 1 (PD-1) therapy. Results on the association between PD-L1 expression and survival among patients with a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sorensen, Steffen Filskov, Zhou, Wei, Dolled-Filhart, Marisa, Georgsen, Jeanette Baehr, Wang, Zhen, Emancipator, Kenneth, Wu, Dianna, Busch-Sørensen, Michael, Meldgaard, Peter, Hager, Henrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2016
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800057/ https://www.ncbi.nlm.nih.gov/pubmed/26947883 http://dx.doi.org/10.1016/j.tranon.2016.01.003

Ejemplares similares

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer
por: Roach, Charlotte, et al.
Publicado: (2016)

Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer
por: Cho, Jong Ho, et al.
Publicado: (2018)

Quantitative Assessment of Tissue Biomarkers and Construction of a Model to Predict Outcome in Breast Cancer Using Multiple Imputation
por: Emerson, John W., et al.
Publicado: (2008)

Association of programmed death ligand 1 expression with prognosis among patients with ten uncommon advanced cancers
por: Steiniche, Torben, et al.
Publicado: (2020)

Computational and Bioinformatics Frameworks for Next-Generation Whole Exome and Genome Sequencing
por: Dolled-Filhart, Marisa P., et al.
Publicado: (2013)

Diffuse Abdominal Splenosis Mimicking Peritoneal Metastases in a 35-Year-Old Man with a Resectable Carcinoma of the Ampulla of Vater
por: Sorensen, Steffen Filskov, et al.
Publicado: (2013)

Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor—a Danish cohort study
por: Dissing, Julie Gabe, et al.
Publicado: (2022)

Computer-Assisted Annotation of Digital H&E/SOX10 Dual Stains Generates High-Performing Convolutional Neural Network for Calculating Tumor Burden in H&E-Stained Cutaneous Melanoma
por: Nielsen, Patricia Switten, et al.
Publicado: (2022)

Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications
por: Vainer, Gilad, et al.
Publicado: (2023)

Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays
por: Weber, Britta, et al.
Publicado: (2014)

Pregnancy-Associated Plasma Protein-A2 Is Associated With Mortality in Patients With Lung Cancer
por: Hjortebjerg, Rikke, et al.
Publicado: (2020)

Systemic Inflammation Associates With a Myeloid Inflamed Tumor Microenvironment in Primary Resected Colon Cancer—May Cold Tumors Simply Be Too Hot?
por: Køstner, Anne Helene, et al.
Publicado: (2021)

Tumor Ulceration, Reduced Infiltration of CD8-Lymphocytes, High Neutrophil-to-CD8-Lymphocyte Ratio and Absence of MC Virus are Negative Prognostic Markers for Patients with Merkel Cell Carcinoma
por: Naseri, Simon, et al.
Publicado: (2020)

Intra‐individual variation of circulating tumour DNA in lung cancer patients
por: Hojbjerg, Johanne A., et al.
Publicado: (2019)

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2006)

Prognostic significance of T‐cell–inflamed gene expression profile and PD‐L1 expression in patients with esophageal cancer
por: Steiniche, Torben, et al.
Publicado: (2021)

Circulating immune response proteins predict the outcome following disease progression of osimertinib treated epidermal growth factor receptor-positive non-small cell lung cancer patients
por: Maansson, Christoffer T., et al.
Publicado: (2023)

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
por: Demuth, Christina, et al.
Publicado: (2018)

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
por: Gualberto, A, et al.
Publicado: (2011)

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
por: Gualberto, A, et al.
Publicado: (2012)

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
por: Ulhoi, Maiken Parm, et al.
Publicado: (2021)

Blood tumor mutational burden and dynamic changes in circulating tumor DNA predict response to pembrolizumab treatment in advanced non-small cell lung cancer
por: Stensgaard, Simone, et al.
Publicado: (2023)

Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis
por: Guo, Xiaodi, et al.
Publicado: (2020)

MicroRNA-126 and epidermal growth factor-like domain 7 predict recurrence in patients with colon cancer treated with neoadjuvant chemotherapy
por: Hansen, Torben Frøstrup, et al.
Publicado: (2019)

Use of administrative hospital registry data and a civil registry to measure survival and other outcomes after cancer
por: Sørensen, Henrik Toft, et al.
Publicado: (2011)

Association between Early Immune-Related Adverse Events and Survival in Patients Treated with PD-1/PD-L1 Inhibitors
por: Zhang, You-Cheng, et al.
Publicado: (2023)

Fueling the flames of colon cancer – does CRP play a direct pro-inflammatory role?
por: Køstner, Anne Helene, et al.
Publicado: (2023)

Upregulation of Mrps18a in breast cancer identified by selecting phage antibody libraries on breast tissue sections
por: Sørensen, Karen Marie Juul, et al.
Publicado: (2017)

Gene Expression of the EGF System—a Prognostic Model in Non–Small Cell Lung Cancer Patients Without Activating EGFR Mutations()
por: Sandfeld-Paulsen, Birgitte, et al.
Publicado: (2016)

A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations
por: Demuth, Christina, et al.
Publicado: (2018)

Cell‐free chromatin immunoprecipitation can determine tumor gene expression in lung cancer patients
por: Trier Maansson, Christoffer, et al.
Publicado: (2023)

High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy
por: Krafft, Ulrich, et al.
Publicado: (2021)

Neoadjuvant PD-1 Inhibitor Plus Apatinib and Chemotherapy Versus Apatinib Plus Chemotherapy in Treating Patients With Locally Advanced Gastric Cancer: A Prospective, Cohort Study
por: Wang, Chunjing, et al.
Publicado: (2023)

Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation
por: Sorensen, Flemming Brandt, et al.
Publicado: (2008)

Socioeconomic status and survival of cirrhosis patients: A Danish nationwide cohort study
por: Jepsen, Peter, et al.
Publicado: (2009)

The impact of comorbidity on cancer survival: a review
por: Søgaard, Mette, et al.
Publicado: (2013)

Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2016)

Monitoring of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Sensitizing and Resistance Mutations in the Plasma DNA of Patients With Advanced Non–Small Cell Lung Cancer During Treatment With Erlotinib
por: Sorensen, Boe S, et al.
Publicado: (2014)

Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients()
por: Winther-Larsen, Anne, et al.
Publicado: (2016)

Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients
por: Madsen, Anne Tranberg, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v368l8lr92m31cod6him0440rf